2025-10-29 10:15:13
Presenters: Desai SR,1,2 Lain E,3 Elbuluk N,4 Frey C5
Affiliations: 1Department of Dermatology, The University of Texas Southwestern Medical Center, Dallas, TX; 2Innovative Dermatology, Plano, TX; 3Sanova Dermatology, Austin, TX; 4Department of Dermatology, Keck School of Medicine, University of Southern California, Los Angeles, CA; 5Department of Dermatology, Howard University Hospital, Washington DC
Background: Skin hyperpigmentation, which includes melasma, post-inflammatory hyperpigmentation, and solar lentigines, significantly impacts patients’ quality of life. The overproduction of melanin occurs via a complex mechanism and is mediated by activation of the human skin enzyme tyrosinase through conversion of L-Dopa to the end product melanin with subsequent deposition in skin. Thiamidol-based formulations have been previously shown to be effective in reducing the visible factors associated with this human skin enzyme.
Objective: The objective of this research was to investigate the clinical efficacy of a novel cosmetic Thiamidol-containing serum and Thiamidol-containing regimen (Day Lotion with SPF 30, Serum, and Night Cream) for the visible management of facial hyperpigmentation.
Methods: A randomized study was performed with 90 subjects (representative of Fitzpatrick Skin Types I-VI) clinically presenting with facial hyperpigmentation as measured by colorimeter and individual typology angle (ITA0) (Thiamidol serum n=43; Thiamidol regimen n=47), to assess the efficacy of a Thiamidol-based serum (2x daily application; morning/night) or a Thiamidol-based regimen (Day lotion with SPF 30 + Serum in morning; Night cream + Serum at night) for 12 weeks with a 6-week regression period. Assessments of skin lightness (L*), ITA0 value, radiance, and shine were conducted at baseline, Weeks 2, 4, 8, 12, and 18.
Results: A significant visible reduction in facial hyperpigmentation, assessed by increases in L* and ITA° values, along with an increase in skin radiance and shine, were observed as early as Week 2, with continued improvement through Week 12 in both the Serum and Regimen groups relative to baseline. Changes in radiance and shine were enhanced in the regimen-treated group compared to serum alone by Week 8 and extending to Week 12.
Discussion: This study demonstrates the clinical effectiveness of Thiamidol-containing formulations in the visible improvement of facial hyperpigmentation and in overall skin radiance and shine. Use of the Thiamidolcontaining serum twice daily resulted in a significant visible improvement of facial hyperpigmentation, while use of the serum in combination with the day lotion with SPF 30 and the night cream, further enhanced the efficacy on radiance and shine.
Conclusion: These data support the use of Thiamidol-containing formulations as part of the overall management strategy for individuals affected by facial hyperpigmentation.
Funding: Scientific poster submission support provided by Beiersdorf, Inc.
©Matrix Medical Communications. View All Articles.